Bristol Advancing Two New Mechanisms In HIV, With Focus On Treatment-Experienced Patients
Executive Summary
An attachment inhibitor entering Phase III may offer a new option for patients who have outlived the utility of other antiretrovirals. Bristol also is advancing a second-generation maturation inhibitor of HIV into Phase IIb studies, hoping to succeed where other candidates failed to address viral mutation.
You may also be interested in...
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
Bristol Offloads HIV Pipeline To ViiV As It Tightens Focus
Deal brings GSK/Pfizer HIV-focused affiliate two novel mechanisms, one of which could be used in combination with Tivicay and another that addresses a different stage of the virus' lifecycle than any HIV drug now approved.
Bristol Drops Virology Discovery In Latest R&D Reshuffling
Firm plans to expand presence in Boston and San Francisco, while shuttering or de-emphasizing other locations, and to end virology discovery, in line with R&D strategy introduced in 2013.